Premium
Glutamate release inhibition ineffective in Levodopa‐induced motor complications
Author(s) -
BaraJimenez William,
Dimitrova Tzvetelina D.,
Sherzai Abdullah,
Aksu Murat,
Chase Thomas N.
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20976
Subject(s) - glutamatergic , levodopa , glutamate receptor , riluzole , parkinson's disease , medicine , dyskinesia , neuroscience , neurotransmission , pharmacology , anesthesia , psychology , disease , receptor
Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3‐week, double‐blind, proof‐of‐concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa‐induced motor complication severity. Opposing effects of a generalized inhibition of glutamate‐mediated synaptic transmission may limit the usefulness of this approach to treat PD. © 2006 Movement Disorder Society